101 studies found for:    Melanoma (women OR woman OR female)
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma
Condition: Melanoma
Intervention: Behavioral: questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
2 Active, not recruiting Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
Conditions: Breast Cancer;   Genitourinary Cancer;   Malignant Female Reproductive System Neoplasm;   Melanoma;   Sarcoma
Intervention: Procedure: Punch Biopsy
3 Completed Microarray Analysis for Human Genetic Disease
Conditions: Breast Neoplasm;   Hereditary Neoplastic Syndrome;   Melanoma;   Ovarian Neoplasm
Intervention:
4 Completed Vaccine Therapy in Treating Patients With Metastatic Cancer
Conditions: Lung Cancer;   Adult Soft Tissue Sarcoma;   Colorectal Cancer;   Bone Cancer;   Ovarian Sarcoma;   Melanoma;   Colon Cancer;   Rectal Cancer;   Breast Cancer;   Eye Cancer;   Uterine Sarcoma
Interventions: Drug: interleukin-2;   Drug: MAGE-12 peptide vaccine;   Drug: Montanide ISA-51
5 Completed Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Vinorelbine;   Drug: Docetaxel;   Drug: Sargramostim
6 Recruiting Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: DC vaccine;   Drug: Dasatinib
7 Completed Disulfiram in Patients With Metastatic Melanoma
Condition: Stage IV Melanoma
Intervention: Drug: Disulfiram (DSF)
8 Completed
Has Results
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
Condition: Metastatic Malignant Melanoma
Interventions: Drug: Avastin;   Drug: Abraxane
9 Unknown  Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
10 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
11 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: quality-of-life assessment
12 Completed Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: alvocidib
13 Recruiting Dendritic Cell Activating Scaffold in Melanoma
Condition: Melanoma
Intervention: Biological: WDVAX
14 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
15 Terminated Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Condition: Melanoma
Intervention:
16 Recruiting Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Condition: Metastatic Melanoma
Intervention: Radiation: WBRT
17 Completed Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: comparative genomic hybridization;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: immunohistochemistry staining method
18 Recruiting Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: dabrafenib;   Biological: ipilimumab;   Drug: trametinib;   Other: laboratory biomarker analysis
19 Recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: cabozantinib-s-malate;   Drug: temozolomide;   Drug: dacarbazine;   Other: laboratory biomarker analysis
20 Recruiting Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: bevacizumab;   Biological: ipilimumab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years